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Abstract
Background: Several studies have reported that minimally invasive surgery (MIS) might be considered for resecting
neuroblastomas without image-defined risk factors (IDRFs); however, there are no studies comparing the outcomes
of laparotomy and laparoscopy in IDRF-negative patients. Thus, we investigated the feasibility of laparoscopic
surgery and compared the two abovementioned approaches.
Methods: To compare the effects of laparotomy with those of laparoscopy in patients with neuroblastomas
without IDRFs, the following items were retrospectively compared: largest tumor dimension, volume of blood loss,
time required to initiate postoperative feeding, locoregional recurrence rate, survival, etc.
Results: Nine patients without IDRFs (three at low-to-medium risk and six at high risk) underwent laparotomy, and
seven patients without IDRFs (two at low-to-medium risk and five at high risk) underwent laparoscopy. Median
duration of surgery was 221 (130–304) and 172 (122–253) min in the laparotomy and laparoscopy groups,
respectively, showing no significant difference. Median postoperative time required for resuming meal consumption
was significantly longer in the laparotomy (4 days; 2–5) group than that in the laparoscopy group (3 days; 2–3; p =
0.023). Median blood loss was significantly higher in the laparotomy group (5 ml/Kg;2.6–16) than that in the
laparoscopy group (2.1 ml/Kg;0.1–4.0; P = 0.037). Median follow-up period was 81 (52–94) and 21 (17–28) months,
locoregional recurrence rates were 22 and 0% at 1 year, 1-year progression-free survival rates were 78 and 100%,
and overall survival rates were 67 and 100% in the laparotomy and laparoscopy groups, respectively, with no
significant differences.
Conclusions: MIS for the treatment of neuroblastomas without IDRFs in low- to high-risk patients is safe and
feasible and does not compromise the treatment outcome.
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Background
Neuroblastoma is a common malignant solid tumor in
pediatric cases that is usually treated by a combination
of observation, surgery, chemotherapy and radiation
therapy. Surgical resection is a part of the multidisciplin-
ary approach, for which it is important to decrease the
general invasiveness and damage to the surrounding tis-
sues and promptly transition to subsequent treatments
[1–3]. Image-defined risk factors (IDRFs) are surgical
risk factors that are evaluated according to the concepts
established by the International Neuroblastoma Risk
Group, as proposed by collaborative studies conducted
in Europe [4, 5]. The significance of preoperative evalu-
ation of surgical risks by internationally integrated stan-
dards that are made possible by IDRFs is remarkable,
and the establishment of standardized criteria for and
assessment of not only the advisability of surgery but
also the selection of surgical procedure is expected. The
prevalence of clinical studies on surgery using IDRFs is
anticipated to increase in future.
Compared with laparotomy, laparoscopic surgery is
generally associated with rapid recovery and less inva-
siveness [6, 7]. Laparoscopic surgical resection for
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selected pediatric malignant solid tumors was found to
be both feasible and safe [8, 9]. Long-term follow-up
data are essential to confirm its oncologic safety [10],
and several reports have claimed that minimally invasive
surgery (MIS) might be considered to resect neuroblas-
tomas without IDRFs [11, 12]. Minimally invasive adre-
nalectomy is a promising approach for the resection of
small adrenal tumors, and benign diseases are excellent
candidates for this minimally invasive technique [13].
However, there have been no studies comparing laparot-
omy and laparoscopy for the treatment of neuroblasto-
mas in low- to high-risk patients without IDRFs. Thus,
we investigated the feasibility of laparoscopic surgery
and attempted to compare both these approaches in
IDRF-negative patients.
Methods
Prior to this study, all protocols were approved by the eth-
ics review board of our institute (approval number: 2015–
0086). The medical records of all patients aged 0–15 years
who underwent total or partial resection of abdominal
neuroblastoma at our department between August 2003
and August 2016 were retrospectively reviewed. Laparo-
scopic resection was introduced in February 2014 and was
chosen when the tumor had no IDRF-positive factor ex-
cept contact with renal vessels.
Determination of the therapeutic strategy was based
on the Japan Neuroblastoma Study Group (JNBSG)
protocol, where surgical intervention was considered
when the patients achieved IDRF-negative status and
had no metastatic lesions [14–16]. To evaluate the ef-
fects of laparoscopic surgery, patients with neuroblasto-
mas without IDRFs who underwent laparotomy were
compared with those who underwent laparoscopy. The
following items were retrospectively compared: N-myc
proto-oncogene protein (MYCN), vanillylmandelic acid
(VMA), homovanillic acid (HVA), neuron-specific eno-
lase (NSE), largest tumor dimension, duration of surgery,
volume of blood loss, time required to initiate postoper-
ative feeding, locoregional recurrence rate and survival.
Statistical analysis was performed using the Fisher’s
exact test for categorical variables and Wilcoxon’s signed-
ranktest for continuous variables with JUMP pro ® 11
(SAS Institute Inc., Cary, NC, USA). A p-value of <0.05
was considered statistically significant.
Surgical laparoscopic procedure
The patient was placed in the supine or semi-lateral de-
cubitus position, three flaps were created in the umbil-
icus in an inverted Y shape, a multi-port device was
inserted, and the first port was placed [17]. Through the
multi-port device, one or two additional ports and one
or two working ports were inserted in the abdomen, and
abdominal air pressure of 8–10 mmHg was applied.
Resection was performed using laparoscopic coagulating
shears. Then, the resected tumor was placed in a speci-
men retrieval bag and removed through the umbilical
layer if it was 5 cm or less in diameter or by performing
an additional Pfannenstiel incision if larger.
Results
Thirty-four patients (six at low-to-medium risk and 28
at high risk) underwent laparotomy, and nine patients
(two at low-to-medium risk and seven at high-risk)
underwent laparoscopy. The proportion of IDRF-
negative patients in the laparoscopy group was signifi-
cantly greater than that in the laparotomy group (78%
vs. 26%; p = 0.008). No differences in sex, age, MYCN,
VMA, HVA, NSE or tumor size (largest tumor dimen-
sion) were apparent between the groups. Only one of
the two IDRF positive case was converted to laparotomy
(Table 1).
In the laparotomy group, total resection was per-
formed in nine out of 25 IDRF-positive patients; partial
resection was performed in the remaining 16 (Fig. 1).
In the laparoscopic group, one of two IDRF-positive
patients was converted from laparoscopy to laparotomy
during the course of the procedure; dissection was diffi-
cult because of strong adhesions around the renal ves-
sels. IDRF was positive in this case, and the renal artery
was encased by the tumor so he underwent laparotomy
with partial resection. The other IDRF-positive patient
underwent laparoscopy with total resection (Fig. 2).
Nine IDRF-negative patients (three at low-to-medium
risk and six at high risk) underwent laparotomy, and
seven IDRF-negative patients (two at low-to-medium
risk and five at high risk) underwent laparoscopy (Fig. 1),
and the outcomes were compared between the two
groups. Seven of the 9 cases in the laparotomy group
and 5 of the 7 cases in the laparoscopy group received
neoadjuvant chemotherapy, consisting of vincristine,
cyclophosphamide, ifosfamide, doxorubicin, pirarubicin,
cisplatin, carboplatin and etoposide, based on the JNBSG
risk-matched multidrug regimen. Total resection was
performed in all patients. There were apparent differ-
ences in age, sex, body weight, Kaup index, MYCN,
VMA, HVA, NSE and tumor size (largest tumor dimen-
sion) between the groups. The following items were
compared between IDRF-negative patients who under-
went laparotomy (n = 9) or laparoscopy (n = 7): duration
of surgery, volume of blood loss, time required for initi-
ating postoperative meal consumption, locoregional re-
currence at 1 year, and survival. The median duration of
surgery was 221 min (130–304) in the laparotomy group
and 172 min (122–253; p = 0.626) in the laparoscopy
group, indicating no significant difference. The median
duration to resume meal consumption was significantly
longer in the laparotomy group (4 days; 2–5) than that
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in the laparoscopy group (3 days; 2–3; p = 0.023). The me-
dian volume of blood loss was significantly higher in the
laparotomy group (5 mL/kg body weight; 2.6–16) than
that in the laparoscopy group (2.1 mL/kg body weight;
0.1–4.0; p = 0.037). The median follow-up period was 81
and 21 months, locoregional recurrence rates at 1 year
were 22% (2 of 9 cases) and 0%, 1-year progression-free
survival rates were 78 and 100%, and overall survival rates
were 67 and 100% in the laparotomy and laparoscopy
groups, respectively, indicating no significant differences
(Table 2). No surgical complications (greater than Grade
II severity, according to the Dindo classification) were ob-
served in the IDRF-negative group [18].
Comparing conditions between the initial visit and
pre-surgery (after neoadjuvant therapy) among the
IDRF-negative patients, we found that the tumor size
markedly decreased at pre-surgery (3.4 cm; range,
1.1–8.7; p = 0.031) compared with the initial visit
(5.2 cm; range, 3.1–11.3). In addition, five patients
who underwent laparoscopic resection transitioned
from IDRF-positive to IDRF-negative after chemother-
apy. For example, in Case 1 (a 28-month-old male at
high risk), although the tumor was found to envelop
the renal vessels at the initial visit, the tumor size
markedly decreased (from 9.0 cm to 4.6 cm) and
IDRFs were absent on imaging after chemotherapy
Table 1 Resection of abdominal neuroblastoma performed between August 2003 and 2016
Laparotomy (n = 34) Laparoscopy (n = 9) p
Total laparoscopic resection 8 (89%) Conversion 1 (11%)
Removal Total 18 (53%) Partial 16 (47%) Total 8 (100%) Partial 1 (100%)
Age (months) a 45 [12–60] 28 [21.5–51] 0.300
Sex males 12 (35%) females 22 (65%) males 5 (56%) females 4 (44%) 0.440
IDRF (%) IDRF+ 25 (74%) IDRF− 9 (26%) IDRF+ 2 (22%) IDRF− 7 (78%) 0.008b







HVA (mg/gCr) a 16.1 [13.1–23.8] 18.2 [11.2–43.3] 0.702
VMA (mg/gCr) a 9.70 [8.9–17.8] 9.1 [4.0–24.7] 0.702
NSE (ng/mL) a 11.4 [9.0–15.7] 19.1 [11.0–21.0] 0.051
Largest tumor dimension (cm) a 4.0 [3.0–6.0] 4.3 [2.6–4.8] 0.704
IDRF image-defined risk factor, MYCN N-myc proto-oncogene protein, VMA vanillylmandelic acid, HVA homovanillic acid, NSE neuron-specific enolase
aMedian [Interquartile range]
bThis p value shows that the proportion of IDRF-negative patients in the laparoscopy group was significantly greater than that in the laparotomy group
Fig. 1 Patient and risk-group stratifications
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(Fig. 3). This patient remained progression-free for
24 months after laparoscopic surgery. In Case 2 (a
51-month-old male at low risk), the tumor size was
8.7 cm and IDRFs were absent; thus, we performed
laparoscopic total excision and removed the tumor
through a Pfannenstiel incision without any complica-
tion (Fig. 4). This patient remained progression-free
for 16 months after surgery.
Discussion
The advantages of MIS compared with those of open
surgery, include marked reduction in postoperative pain
and surgical site infection, and cosmesis [19]. Accord-
ingly, there were significant differences in the volume of
blood loss and time required to initiate postoperative
feeding between laparotomy and laparoscopy for IDRF-
negative patients. Thus, we considered that laparoscopy
Fig. 2 A 51-month-old girl (International Neuroblastoma Staging System [INSS]: stage 4, Children’s Oncology Group [COG] risk: high, surgical duration:
202 min, and blood loss: 3 mL). Total resection was laparoscopically performed. On her first visit, imaging studies showed that the renal vessels and
aorta were encased by the tumor. After neoadjuvant chemotherapy, the tumor was seen to be in contact with the right renal vessels only. Outcome:
progression-free survival, 23 months
Table 2 Characteristics of IDRF-negative patients who underwent laparotomy or laparoscopic tumor resection
Laparotomy (n = 9) Laparoscopic surgery (n = 7) p
Risk Low/intermediate 3 (33%) High 6 (67%) Low/intermediate 2 (29%) High 5 (71%) 0.838
Surgery total removal 9 (100%) total removal 7 (100%)
Age (month) a 12 [9.5–48] 28 [23–51] 0.143
Sex male 6 (67%) female 3 (33%) male 3 (43%) female 4 (57%) 0.615
Body weight (kg) a 8.65 [8.09–15.2] 11.8 [10.3–14.9] 0.143
Kaup index a 15.32 [13.87–16.65] 15.67 [15.51–16.45] 0.626
MYCN amplified amplified 2 (22%),
single copy 2 (22%),
unknown 5 (56%)
amplified 2 (29%),
single copy 2 (29%),
unknown 3 (43%)
0.771
VMA (mg/gCr) a 11.1 [9.6–17.0] 9.1 [7.8–19.8] 0.805
HVA (mg/gCr) a 21 [17.7–30.3] 18.2 [11.2–30.4] 0.805
NSE (ng/mL) a 9.6 [8.0–29.4] 19.3 [12.4–21.0] 0.326
Largest tumor dimension at surgery (cm) a 3.3 [2.9–4.1] 3.6 [2.7–5.0] 0.626
Duration of surgery (min) a 221 [130–304] 172 [122–253] 0.626
Loss of blood volume (mL/kg) a 5 [2.6–16] 2.1 [0.1–4.0] 0.037b
Time to start postoperative feeding (days) a 4 [2–5] 3 [2–3] 0.023b
Locoregional recurrence (1 year) 22% 0% 0.475
Progression-free survival (1 year) 78% 100% 0.414
Overall survival (1 year) 67% 100% 0.231
Follow up (months) a 81 [52–94] 21 [17–28]
IDRF image-defined risk factor, MYCN N-myc proto-oncogene protein, VMA vanillylmandelic acid, HVA homovanillic acid, NSE neuron-specific enolase
aMedian [Interquartile range] bSignificant differences
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was feasible for IDRF-negative patients. However, the
tumor size limit for laparoscopic excision is unclear, and
most reports have supported the indication of laparo-
scopic excision for tumors <4–6 cm [7, 20, 21]. In our
laparoscopic IDRF-negative cases, the tumor sizes at op-
eration were 1.1, 2.7, 2.8, 3.6, 4.6, 5.0 and 8.7 cm.
Because no obvious vascular involvement was present,
we determined that the patient (Case 2) could undergo
laparoscopic total resection and proceeded with the sur-
gery. Five patients who underwent laparoscopic resec-
tion transitioned to IDRF-negative after chemotherapy.
This finding indicates the importance of the timing of
surgery in advanced cases. Simon et al. reported that
246 of 278 patients with stage 4 neuroblastoma aged
18 months or older did not undergo surgery prior to
chemotherapy [22]. Kelleher et al. compared the clinical
Fig. 3 (Case 1): A 28-month-old boy (International Neuroblastoma Staging System [INSS]: stage 4, Children’s Oncology Group [COG] risk: high,
surgical duration: 146 min, and blood loss: 53 mL). Total resection was laparoscopically performed. Outcome: progression-free
survival, 24 months
Fig. 4 [Case 2 (pre-surgery)]: A 51-month-old boy (International Neuroblastoma Staging System [INSS]: stage 1, Children’s Oncology Group [COG]
risk: low, surgical duration: 253 min, and blood loss: 61 mL). Total resection was laparoscopically performed. The tumor was in contact with the
aorta, but renal vessels were intact. Outcome: progression-free survival, 16 months
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outcomes between laparotomy and laparoscopy, includ-
ing advanced cases and found no difference in mortality
among patients who met the selection criteria for the
laparoscopic resection which were absence of vascular
encasement and size <5 cm as the greatest dimension.
Other patients underwent laparotomy [19, 23].
We performed neuroblastoma resection in 13 patients
after introducing laparoscopic surgery, and of these, four
underwent laparotomy (all were IDRF-positive) and nine
underwent laparoscopy (two IDRF positive for contact
with or encasement of renal vessels and seven IDRF
negative). One IDRF-positive patient with encasement of
renal vessels was converted from laparoscopy to laparot-
omy because dissection appeared difficult owing to
strong adhesion with renal vessels. Partial resection
under laparotomy was performed in this patient, and we
had to carefully determine the indication for laparos-
copy, considering the obvious vascular involvement in
this case. The tumor in the other IDRF-positive patient
made contact with the renal vessels and inferior vena
cava; however, dissection was possible by laparoscopic
surgery, and total tumor resection was macroscopically
performed. Furthermore, a negative margin was histo-
pathologically diagnosed. This patient currently remains
progression-free for 23 months after high-dose chemo-
therapy and autologous peripheral blood stem cell trans-
plantation. Although IDRF is positive if renal vessels are
not only encased but also in contact with the tumor, in
our experience, laparoscopic surgery could potentially be
used for contacted cases [11]. Thus, we still considered
IDRF in renal vessels as IDRF-negative. Irtan et al. re-
ported that the completeness resection was related only
to the number of preoperative IDRFs. They treated pa-
tients according to ongoing SIOPEN protocols, which
included a high-risk group who received high-dose
chemotherapy followed by stem cell rescue before sur-
gery. They suggested IDRF assessment after neoadjuvant
chemotherapy is useful in these patients [24].
Another advantage of laparoscopic surgery is a re-
duced risk of intestinal obstruction, which is critical for
pediatric oncology patients, especially if they receive
radiotherapy [25]. In our study, all patients in the lapar-
oscopy group started oral feeding within 3 days after
surgery and no patients presented symptoms of ileus.
However, we had too few cases to prove the competitive
advantage of laparoscopy over laparotomy.
The results of the present study showed no differences
in short-term prognosis between these two procedures;
thus, we believe that laparoscopic surgery can achieve
favorable outcomes comparable to those of laparotomy
in IDRF-negative patients, even those considered at high
risk.
This study was limited by its small sample size and
short observation period. Future studies involving more
patients and a longer follow-up period are warranted.
Moreover, because this was a single-center, retrospective
study, a multicenter, prospective study would be ideal to
assess the merits of minimally invasive surgery for this
patient population.
This is the first report for the treatment of neuroblast-
oma comparing laparotomy and laparoscopy for the
treatment of neuroblastoma without IDRFs.
Conclusions
Although the limited number of cases and short-term
observation period prevented the investigation of long-
term outcomes, we found that laparoscopic surgery was
a feasible minimally invasive procedure for the resection
of neuroblastoma, particularly in IDRF-negative patients.
Further studies focused on oncologic and safety out-
comes are warranted to assess the merits of this surgical
approach in neuroblastomas.
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